2023
DOI: 10.3390/ijms24065175
|View full text |Cite
|
Sign up to set email alerts
|

β-Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered Aβ Fibrillar Structure

Abstract: The aggregation of amyloid beta (Aβ) into fibrillar aggregates is a key feature of Alzheimer’s disease (AD) pathology. β-carotene and related compounds have been shown to associate with amyloid aggregates and have direct impact on the formation of amyloid fibrils. However, the precise effect of β-carotene on the structure of amyloid aggregates is not known, which poses a limitation towards developing it as a potential AD therapeutic. In this report, we use nanoscale AFM-IR spectroscopy to probe the structure o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 40 publications
0
1
0
Order By: Relevance
“…Consistent with this view, previous reports that have identified carotenoids in plaques have argued that plaques are seen as a type of inflammation by the immune system and that carotenoids accumulate in the plaques to try to stop mitigate the inflammation process. Other studies have suggested that carotenoids can be used in the treatment of AD, reducing cognitive impairment. It is known that β-carotene can inhibit Aβ aggregation, but detailed molecular mechanisms of inhibition are not known. Recent studies by Banerjee et al have shown that β-carotene promotes structural disorder in fibrils but does not necessarily prevent fibril formation. These would lead to expectations that carotenoids should be associated with plaques exhibiting lesser β-sheet character.…”
Section: Resultsmentioning
confidence: 99%
“…Consistent with this view, previous reports that have identified carotenoids in plaques have argued that plaques are seen as a type of inflammation by the immune system and that carotenoids accumulate in the plaques to try to stop mitigate the inflammation process. Other studies have suggested that carotenoids can be used in the treatment of AD, reducing cognitive impairment. It is known that β-carotene can inhibit Aβ aggregation, but detailed molecular mechanisms of inhibition are not known. Recent studies by Banerjee et al have shown that β-carotene promotes structural disorder in fibrils but does not necessarily prevent fibril formation. These would lead to expectations that carotenoids should be associated with plaques exhibiting lesser β-sheet character.…”
Section: Resultsmentioning
confidence: 99%
“…In a subsequent investigation, the precise mechanism by which β-carotene regulates Aβ aggregation was unveiled, which does not relate to the direct inhibition of Aβ fibrillation or alteration of the morphology of Aβ 42 aggregates. Instead, they discovered that β-carotene modulates Aβ aggregation by promoting fibrillar polymorphs devoid of the structural order required for the formation of fibrillar aggregates [ 97 ]. β-carotene has also been identified as an effective competitive inhibitor for AChE with a binding mode similar to that of rivastigmine and galantamine, suggesting that it may be employed as a natural pharmaceutical for the management of AD [ 98 ].…”
Section: Neuroprotective Effects Of Macroalgae- and Microalgae-derive...mentioning
confidence: 99%